EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer

Jacob I Taylor iD, Ashish M Kamat, Michael A O'Donnell iD, Drupad Annapureddy, Jeffrey Howard iD, Wei Shen Tan, Ian McElree iD, Facundo Davaro, Kendrick Yim, Stephen Harrington, Elizabeth Dyer, Anna J Black und 12 weitere

BJU International · 2025

DOI: 10.1111/bju.16509 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift BJU International, 2025. Verfasst von Jacob I Taylor und 23 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas Southwestern Medical Center, Dallas, TX, USA. Hauptthemen laut MEDLINE: BCG Vaccine, Cystectomy, Non-Muscle Invasive Bladder Neoplasms, Organ Sparing Treatments. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To quantify the oncological risks of bladder‐sparing therapy (BST) in patients with Bacillus Calmette–Guérin (BCG)‐unresponsive non‐muscle‐invasive bladder cancer (NMIBC) compared to upfront radical cystectomy (RC). Patients and Methods Pre‐specified data elements were collected from retrospective cohorts of patients with BCG‐unresponsive NMIBC from 10 international sites. After Institutional Review Board approval, patients were included if they had BCG‐unresponsive NMIBC meeting United States Food and Drug Administration criteria. Oncological outcomes were collected following upfront RC or BST. BST regimens included re‐resection or surveillance only, repeat BCG, intravesical chemotherapy, systemic immunotherapy, and clinical trials.

Results

Among 578 patients, 28% underwent upfront RC and 72% received BST. The median (interquartile range) follow‐up was 50 (20–69) months. There were no statistically significant differences in metastasis‐free survival, cancer‐specific survival, or overall survival between treatment groups. In the BST group, high‐grade recurrence rates were 37% and 52% at 12 and 24 months and progression to MIBC was observed in 7% and 13% at 12 and 24 months, respectively. RC was performed in 31.7% in the BST group and nodal disease was found in 13% compared with 4% in upfront RC ( P = 0.030).

Conclusion

In a selected cohort of patients, initial BST offers comparable survival outcomes to upfront RC in the intermediate term. Rates of recurrence and progression increase over time especially in patients treated with additional lines of BST.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BCG VaccineCystectomyNon-Muscle Invasive Bladder NeoplasmsOrgan Sparing TreatmentsUrinary Bladder NeoplasmsAgedFemaleHumansMaleMiddle AgedAdjuvants, ImmunologicNeoplasm InvasivenessNeoplasm Recurrence, LocalRetrospective StudiesTreatment OutcomeFollow-Up Studies

Stichwörter der Autor:innen

BCG‐unresponsiveBladder‐sparing therapyintravesical therapyradical cystectomyurinary bladder neoplasms

Substanzen

Adjuvants, ImmunologicBCG Vaccine

Autor:innen und Institutionen

  • University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • University of Iowa, Iowa City, IA, USA.
  • Moffit Cancer Center, Tampa, FL, USA.
  • Brigham and Women's Hospital, Boston, MA, USA.
  • Penn State Health, Hershey, PA, USA.

ORCID-Profile: Jacob I Taylor, Michael A O'Donnell, Jeffrey Howard, Ian McElree, Mathieu Roumiguié, Roger Li, Yair Lotan

Zitieren

APA

Taylor, J. I., Kamat, A. M., O'Donnell, M. A., Annapureddy, D., Howard, J., Tan, W. S., McElree, I., Davaro, F., Yim, K., Harrington, S., Dyer, E., Black, A. J., Kanabur, P., Roumiguié, M., Lerner, S., Black, P. C., Raman, J. D., Preston, M. A., Steinberg, G., …, & Lotan, Y. (2025). Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer. BJU International. https://doi.org/10.1111/bju.16509

Vancouver

Taylor JI, Kamat AM, O'Donnell MA, Annapureddy D, Howard J, Tan WS, et al. Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer. BJU International. 2025. doi:10.1111/bju.16509

BibTeX
@article{Taylor2025,
  author = {Taylor, Jacob I and Kamat, Ashish M and O'Donnell, Michael A and Annapureddy, Drupad and Howard, Jeffrey and Tan, Wei Shen and McElree, Ian and Davaro, Facundo and Yim, Kendrick and Harrington, Stephen and Dyer, Elizabeth and Black, Anna J and Kanabur, Pratik and Roumiguié, Mathieu and Lerner, Seth and Black, Peter C and Raman, Jay D and Preston, Mark A and Steinberg, Gary and Huang, William and Li, Roger and Packiam, Vignesh T and Woldu, Solomon L and Lotan, Yair},
  title = {Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer},
  journal = {BJU International},
  year = {2025},
  doi = {10.1111/bju.16509}
}
Kostenlos starten →